The current AD therapies, acetylcholinesterase (AChE) inhibitors (rivastigmine, galantamine, donepezil) and n-methyl-D-aspartate receptor antagonist (memantine), solely slow down the progression of cognitive function decline, their therapeutic effects; thus, remain largely symptomatic, supportive and targeting late phases of the disease [6]. Here, ACHE is linked to Alzheimer disease.